Syncona

Syncona is a leading publicly traded British life sciences investment firm specializing in founding/building innovative biotechnology businesses focused primarily on transformative therapies such as gene/cell therapies and oncology treatments. It manages a diversified active portfolio spanning preclinical to commercial stages across about fourteen core holdings—including notable successes like Autolus’s approved CAR-T product "Aucatzyl" and late-stage ophthalmic/gene therapies via Beacon—and has delivered several lucrative exits historically. In response to ongoing sector headwinds since mid-decade highs during the pandemic era boom-bust cycle, it is now prioritizing value realization from mature assets while exploring new structures to maintain exposure to earlier innovation opportunities if shareholders desire them.